The fruity lemon-orange flavor makes it particularly pleasant to drink without a salty or bitter aftertaste and easy to integrate into your daily routine
Checklist to bring to your clinician Bring this to any appointment: a full list of medicines and supplements, recent lab results if available, any history of liver or kidney disease, and clear goals for weight and metabolic health
Retatrutide is a synthetic peptide developed by Eli Lilly that produced the largest weight-loss results ever recorded in a Phase 2 obesity trial an average of 24.2% body weight reduction at the highest dose over 48 weeks
The approved NHS pathways are: Wegovy (semaglutide) licensed for weight management via NICE TA875 (BMI 35+ with one condition, via tier 3 services) and NICE cardiovascular guidance April 2026 (BMI 27+ with established CVD, via GP) Mounjaro (tirzepatide) licensed for weight management via NICE TA1026 (BMI 35+ with four conditions from June 2026, via tier 3 or QOF GP pathway) Ozempic (semaglutide) NOT approved for NHS weight management
Yes, regular lipid profile monitoring remains essential for patients with known dyslipidaemia or cardiovascular risk factors
